The Significance of Defining Preclinical or Prodromal Parkinson's Disease
Identifieur interne : 000F47 ( Main/Exploration ); précédent : 000F46; suivant : 000F48The Significance of Defining Preclinical or Prodromal Parkinson's Disease
Auteurs : C. Warren Olanow [États-Unis] ; José A. Obeso [Espagne]Source :
- Movement disorders [ 0885-3185 ] ; 2012.
Descripteurs français
- Pascal (Inist)
English descriptors
Abstract
A body of clinical and pathologic evidence supports the concept that there a pre-Parkinson state exists prior to the time when Parkinson's disease (PD) can be formally diagnosed. The ability to define a the preclinical or prodromal PD state has many important implications. First, understanding the timing and sequence of pathologic change that occurs in PD could provide important clues as to the etiology and pathogenesis of PD, and provide insight into cell vulnerability factors. Second, defining a population of patients with preclinical PD would provide a potentially important group of subjects for clinical trials attempting to define disease-modifying therapies. And, finally, being able to determine that a person has PD at an earlier time point than is currently possible would permit the introduction of a putative disease-modifying therapy at a time when it could have more profound and long-lasting effects. This paper reviews the clinical significance of defining preclinical PD.
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: 000199
- to stream PascalFrancis, to step Curation: 002B15
- to stream PascalFrancis, to step Checkpoint: 000019
- to stream Main, to step Merge: 000F98
- to stream Main, to step Curation: 000F47
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">The Significance of Defining Preclinical or Prodromal Parkinson's Disease</title><author><name sortKey="Olanow, C Warren" sort="Olanow, C Warren" uniqKey="Olanow C" first="C. Warren" last="Olanow">C. Warren Olanow</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Departments of Neurology and Neuroscience, Mount Sinai School of Medicine</s1><s2>New York, New York</s2><s3>USA</s3><sZ>1 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Obeso, Jose A" sort="Obeso, Jose A" uniqKey="Obeso J" first="José A." last="Obeso">José A. Obeso</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Neurology, University of Navarra</s1><s2>Pamplona</s2><s3>ESP</s3><sZ>2 aut.</sZ></inist:fA14><country>Espagne</country><wicri:noRegion>Pamplona</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">12-0223373</idno><date when="2012">2012</date><idno type="stanalyst">PASCAL 12-0223373 INIST</idno><idno type="RBID">Pascal:12-0223373</idno><idno type="wicri:Area/PascalFrancis/Corpus">000199</idno><idno type="wicri:Area/PascalFrancis/Curation">002B15</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">000019</idno><idno type="wicri:doubleKey">0885-3185:2012:Olanow C:the:significance:of</idno><idno type="wicri:Area/Main/Merge">000F98</idno><idno type="wicri:Area/Main/Curation">000F47</idno><idno type="wicri:Area/Main/Exploration">000F47</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">The Significance of Defining Preclinical or Prodromal Parkinson's Disease</title><author><name sortKey="Olanow, C Warren" sort="Olanow, C Warren" uniqKey="Olanow C" first="C. Warren" last="Olanow">C. Warren Olanow</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Departments of Neurology and Neuroscience, Mount Sinai School of Medicine</s1><s2>New York, New York</s2><s3>USA</s3><sZ>1 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Obeso, Jose A" sort="Obeso, Jose A" uniqKey="Obeso J" first="José A." last="Obeso">José A. Obeso</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Neurology, University of Navarra</s1><s2>Pamplona</s2><s3>ESP</s3><sZ>2 aut.</sZ></inist:fA14><country>Espagne</country><wicri:noRegion>Pamplona</wicri:noRegion></affiliation></author></analytic><series><title level="j" type="main">Movement disorders</title><title level="j" type="abbreviated">Mov. disord.</title><idno type="ISSN">0885-3185</idno><imprint><date when="2012">2012</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Movement disorders</title><title level="j" type="abbreviated">Mov. disord.</title><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Asymptomatic</term><term>Nervous system diseases</term><term>Parkinson disease</term><term>Prodrome</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Maladie de Parkinson</term><term>Pathologie du système nerveux</term><term>Asymptomatique</term><term>Prodrome</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">A body of clinical and pathologic evidence supports the concept that there a pre-Parkinson state exists prior to the time when Parkinson's disease (PD) can be formally diagnosed. The ability to define a the preclinical or prodromal PD state has many important implications. First, understanding the timing and sequence of pathologic change that occurs in PD could provide important clues as to the etiology and pathogenesis of PD, and provide insight into cell vulnerability factors. Second, defining a population of patients with preclinical PD would provide a potentially important group of subjects for clinical trials attempting to define disease-modifying therapies. And, finally, being able to determine that a person has PD at an earlier time point than is currently possible would permit the introduction of a putative disease-modifying therapy at a time when it could have more profound and long-lasting effects. This paper reviews the clinical significance of defining preclinical PD.</div></front></TEI><affiliations><list><country><li>Espagne</li><li>États-Unis</li></country><region><li>État de New York</li></region></list><tree><country name="États-Unis"><region name="État de New York"><name sortKey="Olanow, C Warren" sort="Olanow, C Warren" uniqKey="Olanow C" first="C. Warren" last="Olanow">C. Warren Olanow</name></region></country><country name="Espagne"><noRegion><name sortKey="Obeso, Jose A" sort="Obeso, Jose A" uniqKey="Obeso J" first="José A." last="Obeso">José A. Obeso</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000F47 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000F47 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= Pascal:12-0223373
|texte= The Significance of Defining Preclinical or Prodromal Parkinson's Disease
}}
| This area was generated with Dilib version V0.6.23. |  |